An observational study in Non Small Cell Lung Cancer, sponsored by AstraZeneca. Completed at 9 sites in Greece. Per ClinicalTrials.gov, last updated 2015-11-20.
Sponsored by AstraZeneca · Observational
The primary objective of the study is to collect epidemiological data on EGFR mutation status [M+(mutation positive), M-(mutation negative)] in a population of predominantly Caucasian ethnicity, and to correlate EGFR mutation status with clinico-pathological characteristics (e.g. smoking status, sex, histology, etc). In particular, the study will aim to determine the frequency of EGFR M+ lung cancers in patients with clinico-pathological characteristics that are not commonly associated with EGFR mutation positivity (i.e., smokers, men, and non-adenocarcinoma).
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's enrollment of 589 is above the median of 189 across 1,514 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with Non Small Cell Lung Cancer
Exclusion Criteria:
Patients with Non Small Cell Lung Cancer, visiting hospital oncology clinics
Epidemiological data on EGFR mutation status (M+, M-) in a population of predominantly Caucasian ethnicity
Time frame: Up to 2,5 years
Clinico-pathological characteristics according to mutation status
Time frame: Up to 2,5 years
Pharmacoeconomic data (resource use) associated with the diagnosis and treatment of EGFR M+ patients
Time frame: Up to 3,5 years
Real-life data on 1st-line treatment decisions in EGFR M+ and M-/Mx(mutation status not evaluable) patients
Time frame: Up to 2,5 years
Clinical outcome data under real life clinical practice in all EGFR M+ patients up to disease progression (PFS, OS, DCR)
Time frame: Up to 3,5 years
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca